Nektar Therapeutics (NKTR)
| Market Cap | 1.93B |
| Revenue (ttm) | 62.60M |
| Net Income (ttm) | -120.74M |
| Shares Out | 27.98M |
| EPS (ttm) | -7.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,068,872 |
| Open | 65.10 |
| Previous Close | 65.90 |
| Day's Range | 64.80 - 69.29 |
| 52-Week Range | 6.48 - 75.67 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 129.83 (+88.21%) |
| Earnings Date | Mar 12, 2026 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro... [Read more]
Financial Performance
In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $129.83, which is an increase of 88.21% from the latest price.
News
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026,...
Nektar Therapeutics to Participate in Two Investor Conferences in March
SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking ...
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy
Nektar Therapeutics (NKTR) is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. REZPEG's unique mechanism expands regulatory T cells, aiming for durable im...
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L...
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy...
Can NKTR Stock Sustain Its 1,000% Rally?
Nektar stock has increased more than 100% within a week and has skyrocketed 1,000% from its 52-week low of $6.50, trading at around $71 as of February 13, 2026. The surge intensified following the com...
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy...
Why Is Nektar Therapeutics Stock Gaining Wednesday?
Nektar Therapeutics (NASDAQ: NKTR) stock surged in premarket trading Wednesday after new long-term data showed its experimental eczema therapy delivered sustained and even deepening disease control t...
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy...
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses obser...
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors gr...
Nektar.io Introduces DIRT: Materials Management for the Construction Industry
Edmonton, Alberta--(Newsfile Corp. - January 15, 2026) - Nektar.io, located at 14420 154 Ave NW, Edmonton, Alberta, T6V 0K8, Canada, a provider of operational software for the construction industry to...
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
Nektar Therapeutics's results from REZOLVE-AA, a trial of rezpegaldesleukin in alopecia areata, have failed to stimulate a rally in the stock. Even with concerns about statistical significance in the ...
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
Nektar Therapeutics (NASDAQ: NKTR) on Tuesday revealed topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin.
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will h...
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Der...
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout
Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing R...
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dos...
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Nektar Therapeutics ( NKTR) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Vivian Wu Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Resea...
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable secu...
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Confere...
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based ...